The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: A randomized controlled trial

This double-blind, randomized, placebo-controlled, two-sequence, two-period crossover study evaluated the efficacy, safety, tolerability, and pharmacokinetics of ascending doses of filapixant in 23 patients with refractory chronic cough. The primary efficacy endpoint was 24-hour cough frequency, measured using the Vitalograph VitaloJAK ambulatory acoustic cough monitoring system.